- For locally advanced cervical esophageal squamous cell carcinoma (ESCC), curative chemoradiotherapy (CCRT) appears “reasonable,” with salvage surgery considered for residual disease.
Why this matters
- The gold standard for cervical ESCC has been radical esophagectomy, with the obvious potential for complications, comorbidity, and adverse effects on QoL.
- CCRT shows promise of similar survival benefit to that of radical surgery.
- Response to CCRT was similar between cervical and matched thoracic ESCC groups.
- Cervical group had better OS, however: 21.4 vs 10.1 months (P=.012).
- Patients in either group with complete response (CR) had better OS.
- Cervical group had more CR: 33% vs 16% (P=.038).
- Those in cervical group with CR had better OS vs those without CR: 42.9 vs 11.6 months (P<.001>
- Number operated in the cervical group without CR (n=3) was small, with no OS differences from CR group.
- 63 patients with cervical ESCC propensity matched for tumor features and age to 63 of 348 with thoracic ESCC.
- Median dose 66 (range, 66-70) Gy for cervical, 50.4 (range, 50-50.4) Gy for thoracic.
- OS compared.
- Funding: National Science Council of Taiwan; Chang Gung Memorial Hospital.
- Retrospective design, single center, small number of patients.